UnitedHealth Group news: institutions increase holdings as price slips below long-term moving averages

Traders Union
All News
Financial News
Unitedhealth slides 1.06% today

Highlights

UnitedHealth Group (UNH) trades at $327.19, well below MA-20 ($356.95), MA-50 ($344.50), and MA-200 ($384.53), reflecting sustained downside momentum across timeframes.
Q4 2023 revenue hit $94.4 billion—up nearly 15% for the year—while operating earnings declined to $1.8 billion due to higher claims and a maturing membership base.
Oscillators like RSI (34.06), Stoch RSI (0.00), and CCI (-222.29) signal extreme oversold conditions, but price is expected to trade sideways near $326 support, with bearish bias prevailing.

Portfolio shifts and margin pressures as revenue growth outpaces earnings

UnitedHealth Group reported strong Q4 2023 financial results with revenue reaching $94.4 billion, representing nearly 15% growth for the full year, fueled by double-digit gains in both UnitedHealthcare and Optum divisions. The company exceeded earnings expectations and raised its 2025 guidance, despite operating earnings declining to $1.8 billion due to higher claims and a maturing membership base, which management described as aligned with forecasts. Institutional investors have increased their holdings, with 87.86% of shares now held, while UnitedHealth continues to focus on portfolio rationalization and operational improvements amid margin pressures and elevated care utilization.

Oversold oscillators and neutral momentum as sellers dominate session

Momentum gauges show a lack of strength, with the D1 MACD remaining neutral and the ADX at 24.58, reflecting some directional activity but no clear trend. Oversold signals dominate with the RSI at 34.06, Stoch RSI completely oversold at 0.00, and CCI at an extreme -222.29, accompanied by a sharply negative BBP indicating sellers are in control through most intraday action. The daily session shows a mild gap down from $330.70 to $327.35, with price near session lows, moderate volatility, and continuing pressure after the open. Some divergences emerge, as momentum is neutral but oscillators are deeply oversold, suggesting the downward pace could stall if sellers exhaust.

Further declines likely as upside probability remains limited

For the next five sessions, the expected price range is $339.25 to $341.68. The probability of a price increase is very low (less than 20%), making further declines more likely in the near term. The baseline scenario calls for sideways trading in a tight range if support remains intact. The bullish case would require a break above $353.80, triggering short covering and targeting higher moving averages. In a bearish scenario, a drop below $326 may open further downside toward recent lows, as longer-term trends remain negative on both daily and weekly charts.

Anton Kharitonov, analyst at Traders Union, notes that despite UnitedHealth's strong revenue growth and institutional demand, technical structure remains notably weak with all key moving averages acting as resistance and multiple momentum indicators deep in oversold territory. He points out that fundamental positives, like improved guidance and portfolio adjustments, are failing to offset short- and long-term bearish price trends, with sentiment still negative as sellers dominate intraday action. The analyst remains cautious, emphasizing that as long as price stays below $353.80 and support at $326 is vulnerable, downside risk prevails. "Base case remains sideways-to-lower as long as the $326–$353.80 range holds — any break beneath support opens the door to new lows, and I would not trust any upside until clear technical reversal," Kharitonov warns.

Last time we reported that mixed momentum and range-bound action signaled ongoing indecision among buyers and sellers. Previously, analysts noted that oscillators indicated oversold conditions even as resistance capped any significant rebound attempts.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.